Cooper CL - Search Results

1

Coronavirus disease 2019 vaccine effectiveness among a population-based cohort of people living with HIV.

Chambers C, Samji H, Cooper CL, Costiniuk CT, Janjua NZ, Kroch AE, Arbess G, Benoit AC, Buchan SA, Chung H, Kendall CE, Kwong JC, Langlois MA, Lee SM, Mbuagbaw L, McCullagh J, Moineddin R, Nambiar D, Walmsley S, Anis AH, Burchell AN; for the COVAXHIV Study Team. Chambers C, et al. Among authors: cooper cl. AIDS. 2022 Dec 1;36(15):F17-F26. doi: 10.1097/QAD.0000000000003405. Epub 2022 Oct 19. AIDS. 2022. PMID: 36254892 Free PMC article.

2

Interpretation of undetectable hepatitis C virus RNA levels in HIV-hepatitis C virus co-infection.

Cooper CL, Cameron DW. Cooper CL, et al. AIDS. 2004 Jan 23;18(2):337-8. doi: 10.1097/00002030-200401230-00029. AIDS. 2004. PMID: 15075557

3

CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults.

Cooper CL, Davis HL, Angel JB, Morris ML, Elfer SM, Seguin I, Krieg AM, Cameron DW. Cooper CL, et al. AIDS. 2005 Sep 23;19(14):1473-9. doi: 10.1097/01.aids.0000183514.37513.d2. AIDS. 2005. PMID: 16135900 Clinical Trial.

4

Pneumocystis jiroveci pneumonia prophylaxis is not required with a CD4+ T-cell count < 200 cells/microl when viral replication is suppressed.

D'Egidio GE, Kravcik S, Cooper CL, Cameron DW, Fergusson DA, Angel JB. D'Egidio GE, et al. Among authors: cooper cl. AIDS. 2007 Aug 20;21(13):1711-5. doi: 10.1097/QAD.0b013e32826fb6fc. AIDS. 2007. PMID: 17690568

5

Evaluation of oral cannabinoid-containing medications for the management of interferon and ribavirin-induced anorexia, nausea and weight loss in patients treated for chronic hepatitis C virus.

Costiniuk CT, Mills E, Cooper CL. Costiniuk CT, et al. Among authors: cooper cl. Can J Gastroenterol. 2008 Apr;22(4):376-80. doi: 10.1155/2008/725702. Can J Gastroenterol. 2008. PMID: 18414712 Free PMC article. Clinical Trial.

6

Erythropoiesis-stimulating agent use for anemia induced by interferon-ribavirin treatment in patients with hepatitis C virus infection is not associated with increased rates of cardiovascular disease, thrombosis, malignancy, or death.

Costiniuk CT, Camacho F, Cooper CL. Costiniuk CT, et al. Among authors: cooper cl. Clin Infect Dis. 2008 Jul 15;47(2):198-202. doi: 10.1086/589243. Clin Infect Dis. 2008. PMID: 18532889

7

HIV-HCV Co-infection therapeutic outcomes have not improved over time.

Cooper C, Costiniuk C, Giguère P. Cooper C, et al. HIV Clin Trials. 2009 May-Jun;10(3):203-6. doi: 10.1310/hct1003-203. HIV Clin Trials. 2009. PMID: 19632960 No abstract available.

8

Once daily dosing improves adherence to antiretroviral therapy.

Raboud J, Li M, Walmsley S, Cooper C, Blitz S, Bayoumi AM, Rourke S, Rueda S, Rachlis A, Mittmann N, Smieja M, Collins E, Loutfy MR. Raboud J, et al. AIDS Behav. 2011 Oct;15(7):1397-409. doi: 10.1007/s10461-010-9818-5. AIDS Behav. 2011. PMID: 20878227

9

Factors associated with virological suppression among HIV-positive individuals on highly active antiretroviral therapy in a multi-site Canadian cohort.

Cescon AM, Cooper C, Chan K, Palmer AK, Klein MB, Machouf N, Loutfy MR, Raboud J, Rachlis A, Ding E, Lima VD, Montaner JS, Rourke SB, Smieja M, Tsoukas C, Hogg RS; CANOC Collaboration. Cescon AM, et al. HIV Med. 2011 Jul;12(6):352-60. doi: 10.1111/j.1468-1293.2010.00890.x. Epub 2010 Nov 8. HIV Med. 2011. PMID: 21059167 Free article.

10

Mortality by baseline CD4 cell count among HIV patients initiating antiretroviral therapy: evidence from a large cohort in Uganda.

Mills EJ, Bakanda C, Birungi J, Mwesigwa R, Chan K, Ford N, Hogg RS, Cooper C. Mills EJ, et al. AIDS. 2011 Mar 27;25(6):851-5. doi: 10.1097/QAD.0b013e32834564e9. AIDS. 2011. PMID: 21330903 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

436 results

Search Page